Disease Landscape and Forecast Insights

Targeted therapies and various biomarkers (e.g., RAS, BRAF, MSI-H,dMMR) play an important role in the treatment of colorectal cancer. Treatment is becoming increasingly segmented by the side on…

The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…

Metformin and sulfonylureas are the most heavily prescribed type 2 diabetes (T2D) drugs and dominate the early lines of therapy before disease progression requires insulin replacement. The…

Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. However, similar to adult CD, the primary goal of the treatment of pediatric CD is to…

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &…

Metastatic squamous non-small-cell lung cancer (NSCLC) is an aggressive form of lung cancer with poor survival outcomes. First-line treatment is limited to chemotherapy or immune checkpoint…

For decades, the treatment landscape of small-cell lung cancer (SCLC) has been dominated by chemotherapy or chemoradiotherapy. In 2018, BristolMyers Squibb’s Opdivo became the first immune…

The Emerging Biosimilars Landscape offers extensive coverage of the global biosimilars development landscape. We track over 520 currently available and novel biosimilar products, detailing…

The development and commercialization of biosimilars require significant investment in capital, resources, and time. Biosimilars developers must ensure that they are equipped with the necessary…

Endometrial cancer is the sixth most common cancer in women worldwide. While the majority of patients present with early stage disease at diagnosis, efficacious therapeutic options for advanced or…

The introduction of immune checkpoint inhibitor therapies, Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combination regimens, such as Roche /…

Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2029. The treatment of metastatic colorectal cancer is…